Shire Launches Cuvitru In U.S. For Primary Immunodeficiency - Quick Facts

Shire plc (SHP.L, SHPG) said it has launched Cuvitru?, the first and only subcutaneous 20 percent treatment option without proline available in the U.S. to treat adult and pediatric patients, two years of age and older, with primary immunodeficiency or PI.

from RTT - Biotech http://ift.tt/2eFkU7Z
via IFTTT